Loading...
Market
Which company will have the highest revenue from diabetes and obesity drugs in Q4 2024?
3
Resolution / Starting Odds
Eli Lilly • 25%
Novo Nordisk • 25%
Sanofi • 25%
Other • 25%
Quarterly financial reports from the companies and market analysis reports
Story
Eli Lilly's Zepbound Cuts Diabetes Risk by 94%, Achieves 23% Weight Loss Over 176 Weeks
Aug 20, 2024, 10:47 AM
Eli Lilly has made significant strides in the pharmaceutical industry with its weight-loss drug, Zepbound. In a long-term study, the drug demonstrated a 94% reduction in the risk of developing type 2 diabetes among adults with pre-diabetes and obesity or overweight. The study, known as SURMOUNT-1, spanned 176 weeks and showed that patients on the highest dose of Zepbound lost 23% of their body weight. This breakthrough has positioned Eli Lilly as a leading player in the obesity and diabetes drug market, narrowing the revenue gap with competitors like Novo Nordisk. The promising results have bolstered investor confidence, contributing to Eli Lilly's status as the world's most valuable drug company.
View original story
Similar markets
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
GlaxoSmithKline • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%